BPG is committed to discovery and dissemination of knowledge
Featured Articles
7/4/2023 9:23:30 AM | Browse: 232 | Download: 560
 |
Received |
|
2023-04-02 12:17 |
|
Peer-Review Started |
|
2023-04-02 12:21 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-04-20 01:16 |
|
Revised |
|
2023-05-26 12:30 |
|
Second Decision |
|
2023-06-19 02:51 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-06-19 07:02 |
|
Articles in Press |
|
2023-06-19 07:02 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2023-06-13 14:52 |
|
Typeset the Manuscript |
|
2023-07-03 14:21 |
|
Publish the Manuscript Online |
|
2023-07-04 08:53 |
| ISSN |
2150-5349 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Hepatitis C virus treatment with glecaprevir and pibrentasvir in patients co-prescribed carbamazepine: Three case reports
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Michael Braude, Dilip T Ratnam, Louise Marsh, Joshua H Abasszade and Anouk T Dev |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Michael Braude, BSc, DPhil, FRACP, MBBS, MSc, Doctor, Department of Gastroenterology and Hepatology, Monash Health, 246 Clayton Road, Clayton 3168, VIC, Australia. mrh.braude@gmail.com |
| Key Words |
Antiepileptic drugs; Drug interactions; Hepatitis C virus; Sustained virological response; Health care access; Case report |
| Core Tip |
Current hepatitis C virus (HCV) direct-acting antiviral (DAA) therapies are not recommended in patients who are co-prescribed carbamazepine. For glecaprevir-pibrentasvir, this is primarily due to carbamazepine’s potent induction of cytochrome P450 3A4 and P-glycoprotein which reduces DAA plasma concentration and may therefore lead to virological failure. Despite theoretical reduction in DAA bioavailability, glecaprevir-pibrentasvir, prescribed over 12-wk, may be an effective treatment for non-cirrhotic patients with HCV who are co-prescribed carbamazepine. Glecaprevir-pibrentasvir should be considered for management of HCV in non-cirrhotic patients who are unable to substitute carbamazepine therapy. Further pharmacokinetic and potency data are required, in addition to further data in patients with cirrhosis. |
| Publish Date |
2023-07-04 08:53 |
| Citation |
Braude M, Ratnam DT, Marsh L, Abasszade JH, Dev AT. Hepatitis C virus treatment with glecaprevir and pibrentasvir in patients co-prescribed carbamazepine: Three case reports. World J Gastrointest Pharmacol Ther 2023; 14(4): 33-38 |
| URL |
https://www.wjgnet.com/2150-5349/full/v14/i4/33.htm |
| DOI |
https://dx.doi.org/10.4292/wjgpt.v14.i4.33 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
